Boehringer's zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 ( ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
The application for this investigational treatment is based on positive results from the Phase Ib Beamion LUNG-1, Cohort 1 trial that demonstrated an objective response rate of 71% in 75 previously treated patients with advanced NSCLC
HER2 ( ERBB2)-mutant advanced NSCLC is linked to poor prognosis and currently has limited treatment options1
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2) mutations and who have received prior systemic therapy. The FDA grants Priority Review to applications for drugs that would offer significant improvements in the treatment, diagnosis, or prevention of serious conditions, with action expected within six months compared to 10 months under standard review. The Prescription Drug User Fee Act (PDUFA) action date is in the third quarter of 2025.
'We believe zongertinib has the potential to transform the care of previously treated patients with HER2 (ERBB2) -mutant advanced non-small cell lung cancer and are hopeful about the continued research in other tumor types and lines of therapy,' said Shashank Deshpande, Member of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. 'Priority Review illustrates the urgent need in this patient population and the possibility for zongertinib to be a groundbreaking innovation for patients with limited treatment options.'
The application was based on results from the positive Phase Ib Beamion LUNG-1 trial. Data from Cohort 1 (N=75) of the study, demonstrated an objective response rate (ORR) of 71% with six-month progression-free survival (PFS) and duration of response (DoR) rates of 69% and 73%, respectively, in patients with mutations in the HER2 tyrosine kinase domain.
Zongertinib had a safety profile with a low incidence of dose reductions (5%) and treatment discontinuations (3%). The majority of treatment-related adverse events (TRAEs) with zongertinib were mild in nature with diarrhea and rash being the most common all grade TRAEs, at 51% and 27% respectively. No new safety signals were observed. Grade 3 or higher TRAEs occurred in one patient treated with zongertinib. No treatment-related interstitial lung disease (ILD) cases were reported.
'Personalized medicine has revolutionized cancer treatment,' said GO2 for Lung Cancer's Chief Scientific Officer, Courtney Granville. 'Early screening and biomarker testing for mutations provide critical information to guide targeted therapies in personalized medicine. This filing acceptance represents a significant step toward offering another option for individuals with a HER2 ( ERBB2) diagnosis, bringing hope and direction to cancer patients.'
Zongertinib was previously granted Breakthrough Therapy Designation and Fast Track Designation by the FDA. The FDA's Breakthrough Therapy designation is intended to expedite the development and review of a medicine that is intended to treat a serious or life-threatening disease, and preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available treatments. The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. In addition to the FDA designations, Japan's Pharmaceuticals and Medical Devices Agency recently granted Orphan Drug Designation to zongertinib.
About the Beamion clinical trial program
Beamion LUNG-1 ( NCT04886804) is an open-label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib as monotherapy in people with unresectable or metastatic solid tumors with HER2 ( ERBB2) alterations. Beamion LUNG-2 is a Phase III, open label, randomized, active-controlled study that is enrolling patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 ( ERBB2) tyrosine kinase domain mutations to evaluate zongertinib compared with standard of care.
About zongertinib
Zongertinib (also known as BI 1810631) is an investigational, irreversible tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 ( ERBB2) while sparing EGFR, thereby limiting associated toxicities. This orally administered, targeted treatment is being developed for HER2 ( ERRB2) - mutant advanced non-small cell lung cancer (NSCLC) and additional clinical studies with zongertinib are ongoing in solid tumors with HER2 alterations.
About non-small cell lung cancer (NSCLC)
Lung cancer claims more lives than any other cancer type and the incidence is set to increase to over 3 million cases worldwide by 2040.2 NSCLC is the most common type of lung cancer.3 Due to a lack of symptoms and misdiagnoses,4 most patients diagnosed with NSCLC present at stage III or IV, where the disease has metastasized locally or to other organs.5 Fewer than 3 in 10 patients are alive five years after a diagnosis of HER2 ( ERBB2)-mutant advanced NSCLC.6 People living with advanced NSCLC can experience a detrimental physical, psychological, and emotional impact on their daily lives. There remains a high unmet need for additional treatment options for people living with advanced NSCLC. HER2 ( ERBB2) mutations occur in approximately 2–4% of NSCLC cases and are associated with a poor prognosis and higher incidence of brain metastases.7,8 Mutations in HER2 ( ERBB2) can lead to overexpression and overactivation, which can in turn result in uncontrolled cell production, inhibition of cell death and promotion of tumor growth and spread.9
About Boehringer Ingelheim in oncology
We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Boehringer Ingelheim's generational commitment to driving scientific innovation is reflected by the company's robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. Boehringer's ambition in oncology is to take a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com/us.
1Nützinger J, Lee JB, Low JL, et al. Lung Cancer. 2023;186:107385. doi:10.1016/j.lungcan.2023.107385
2International Agency for Research on Cancer – World Health Organization. Rates of trachea, bronchus and lung cancer. Available at: https://gco.iarc.fr/tomorrow/en (Accessed: January 2025).
3Zappa C & Mousa Non-small cell lung cancer: current treatment and future advances, Transl Lung Cancer Res. 2016 Jun; 5(3): 288–300.
4American Cancer Society. Signs and Symptoms of Lung Cancer Available at: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/signs-symptoms.html (Accessed: January 2025).
5Casal-Mouriño, A. et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506-518.
6National Cancer Institute Surveillance, Epidemiology, and End Results (SEER). https://seer.cancer.gov/statfacts/html/lungb.html (Accessed: January 2025).
7Baraibar I, et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Crit Rev Oncol Hematol. 2020;148:102906.
8Li, B.T. et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. N Engl J Med. 2022;386:241–51.
9Galogre M, et al. A review of HER2 overexpression and somatic mutations in cancers, Critical Reviews in Oncology/Hematology, Volume 186, 2023, 103997
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
6 hours ago
- Business Upturn
The Pink Salt Trick Recipe for Fast Weight Loss Trend in 2025: Why ProZenith Is the Science-Backed Alternative
Chicago, July 19, 2025 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only. ProZenith is not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Individual results may vary. Always consult a healthcare provider before beginning any supplement or diet strategy. Click Here to Explore the Full ProZenith Formula TL;DR: A trending pink salt recipe is sweeping TikTok as a supposed shortcut for weight loss. But what's really behind this viral drink, and why are experts raising concerns? In this report, we break down the trend's rise, the controversy around AI-generated celebrity endorsements, and how the new supplement ProZenith aims to support hormonal metabolism in a safer, research-backed way. In This Release, You'll Discover: What the 'Pink Salt Trick' recipe really is — and how it became a top 2025 TikTok trend Why AI-generated celebrity videos are being used to fuel misinformation The health risks of using saltwater as a weight loss tool What medical professionals and dietitians are saying about the trend Why women over 30 are most vulnerable to wellness misinformation How ProZenith compares biologically to salt-based hacks What makes ProZenith a better option for long-term metabolic balance Click Here to Learn More About ProZenith What Is the Pink Salt Trick Recipe Everyone's Talking About? The pink salt trick refers to a homemade drink recipe that's gone viral on TikTok and YouTube. It's typically presented as a 'weight loss drink' or 'morning metabolism hack' involving: The Recipe: 1/2 teaspoon pink Himalayan or Hawaiian salt Juice from 1/2 lemon 8–12 oz of warm or room temperature water Optional: 1 tsp apple cider vinegar or a dash of cayenne pepper The promise? Drink it first thing in the morning to 'reset metabolism,' suppress appetite, detox the body, and kickstart fat loss — without caffeine or fasting. Videos promoting the recipe often use phrases like: 'My pants are literally falling off!' 'This is what celebrities are using now.' 'Better than Ozempic!' But the science behind these claims is flimsy at best. And in many cases, entirely fabricated. Despite anecdotal praise, there are no peer-reviewed studies supporting the metabolic effects of pink salt water. Experts say any perceived benefits are likely due to placebo or temporary hydration effects, not real fat loss. The Deepfake Endorsement Controversy: Why the Internet Believed Oprah Promoted the Pink Salt Trick While the drink itself has gone viral, much of the attention in 2025 stems from AI-generated videos of Oprah Winfrey praising the recipe. These videos are so realistic that thousands believed they were real endorsements. In reality, Oprah never promoted the pink salt trick — and she condemned such deepfake scams in a 2022 Instagram video, stating: 'It is a fraud. It is a fake. It's a lie. I have nothing to do with any weight loss gummies or pink salt drinks that claim I use them.' Despite this, new videos using AI facial mapping and voice-cloning tools continue to circulate. Social media platforms have struggled to moderate these videos in real time, which has only contributed to their virality. This issue was spotlighted in Yahoo's creator series — What's Up with the Oprah Pink Salt Trick Recipe for Weight Loss? and What's the Deal with the Miracle Pink Salt Trick for Weight Loss? — where journalist Cassandra Brooklyn described how the fake endorsements kept showing up in her feed even though she never searched for weight loss tips. These articles were later mentioned in a broader industry discussion, including coverage in a GlobeNewswire consumer briefing on ProZenith. Read: Pink Salt Recipe for Weight Loss Spotlighted in New Consumer Briefing on Metabolic Reset with ProZenith Why the Pink Salt Trick Doesn't Work — and Might Be Harmful According to Dr. Alison Childress, a registered dietitian at Texas Tech University: 'Too much sodium can lead to water retention… this could result in weight gain — not fat, but fluid — especially in those who are salt-sensitive.' While the drink may provide a fleeting sense of fullness, there's no thermogenic benefit, hormonal regulation, or appetite suppression involved. Moreover, repeated use of this drink without iodine-rich salt can increase the risk of iodine deficiency, particularly among women of reproductive age. Iodine plays a critical role in thyroid hormone production, and inadequate levels can lead to fatigue, cold sensitivity, dry skin, and weight gain — all symptoms ironically counterproductive to the goals of the pink salt drink. Why Women Over 30 Are Most Vulnerable to These Trends Many women over 30 experience hormonal changes that affect metabolism, energy, and cravings. As stress levels increase and sleep quality declines, quick-fix trends feel even more attractive. Wellness journalist Cassandra Brooklyn explains: 'The pink salt videos started showing up in my feed even though I never searched for them. It made me wonder how many other women were seeing them too — especially those actively looking for help.' Research published in the International Journal of Behavioral Medicine shows that women exposed to 'rapid weight loss' messaging experienced higher body dissatisfaction and stress eating patterns. Compounding the issue is the algorithmic nature of social media, which can push diet content to vulnerable audiences based on a few clicks or likes. For women experiencing hormonal shifts and psychological stress, these seemingly innocent videos can drive harmful behaviors. Why ProZenith Was Formulated for This Exact Challenge ProZenith is a non-stimulant supplement formulated to help women manage appetite, cravings, and metabolic sluggishness without trendy hacks or viral gimmicks. What's Inside: Magnesium + Calcium – Regulate cortisol and stabilize energy – Regulate cortisol and stabilize energy BHB (Beta-Hydroxybutyrate) – Mimics ketone states to curb cravings – Mimics ketone states to curb cravings Turmeric Extract (95% curcuminoids) – Supports inflammation reduction – Supports inflammation reduction BioPerine® – Enhances nutrient absorption and delivery Unlike the pink salt trick, ProZenith doesn't rely on a placebo effect. Its ingredients have been clinically reviewed to support appetite hormones like ghrelin, reduce emotional eating triggers, and help restore metabolic rhythm in women after 30. Each dose is designed for consistency — not intensity. There are no stimulants, no crashes, and no 'flush' reactions. Just gradual, supportive metabolic regulation backed by emerging science and nutritional precision. Explore the Full Ingredient Breakdown Read: ProZenith Ingredients Researched: The Science Behind the Popular Formula Final Thoughts: Why This Trend Matters More Than It Seems The pink salt trick may look harmless. But it reflects a deeper pattern: emotional marketing, AI misinformation, and health shortcuts with no science behind them. ProZenith doesn't promise overnight results. But it does offer a research-supported daily strategy for women who are tired of fads and ready for clarity. If you're navigating hormonal shifts, emotional cravings, or just want to feel steady again — don't fall for digital hype disguised as healing. Support your body with something that respects biology. Click Here to Learn How ProZenith Works About the Brand ProZenith is a non-stimulant nutritional supplement designed to support women navigating hormonal appetite shifts, stress cravings, and metabolism slowdown. With clinically supported ingredients and zero caffeine, ProZenith offers a daily ritual for consistent metabolic support — without buzzwords, gimmicks, or fake endorsements. Customer Support ProZenith – Anti-Craving Support Without Stimulants Email: [email protected] Order Help: Phone (US): 1-800-390-6035 Phone (INT): 1-208-345-4245 Disclaimer This article is for informational purposes only. ProZenith is not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Individual results may vary. Always consult a healthcare provider before beginning any supplement or diet strategy. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
11 hours ago
- Yahoo
FDA Announces Major Recall of Popular Deodorant
It's important to stay informed about recalls, because doing so truly impacts your life. Of course, the sooner you know about a recall, the better, because you can make sure to get rid of the suspecting item and keep everyone in your family safe. "Recalls are important because they protect the public from products that may cause injury, illness or even death," the Food and Drug Administration notes. Now, a large number of Power Stick deodorants manufactured by A.P. Deauville are being recalled for manufacturing defects, according to the Food and Drug Administration. The recall includes more than 67,000 cases of roll-on deodorants that were sold across the United Stated, according to a notice posted by the agency. The problem with the deodorants revolves around deviations with "current good manufacturing practices," a set of guidelines in the pharmaceutical manufacturing industry. The recalled deodorants include the Power Stick for her roll-on Antiperspirant Deodorant Powder Fresh, 1.8 oz/53 mL; the Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh, 1.8 oz/53 mL; and the Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant, 1.8 oz/ 53 mL. Find specific lot numbers on the FDA's website. A press release has not been issued for the recall as of yet. The status of the recall is ongoing. According to the FDA, "A recall is an action taken by a company to correct or remove from the market an FDA regulated product that violates U.S. laws and regulations." They add that "recalls may be initiated voluntarily by a company, or at the request of the FDA." More than 83,000 FDA regulated products were recalled between the years 2014 and 2024. The FDA adds that "most recalls involve removing violative FDA regulated products from the market, but there are instances where a violation can be corrected without removing the products from distribution."FDA Announces Major Recall of Popular Deodorant first appeared on Men's Journal on Jul 19, 2025 Solve the daily Crossword
Indianapolis Star
13 hours ago
- Indianapolis Star
Man dies after being sucked into MRI machine by his own metal necklace
A man who was violently sucked into an MRI machine by a metal chain around his neck has died, police in New York said. The man was wearing a large metallic chain around his neck, which caused him to be drawn into the machine, the Nassau County Police Department said in a news release. The incident took place at the Nassau Open MRI medical facility in the village of Westbury on the North Shore of Long Island. Police responded to the facility just after 4:30 p.m. on July 16. At the scene, witnesses told officers a 61-year-old man "entered an unauthorized M.R.I. room while the scan was in progress," police said. Multiple injuries in incident: Over 2 dozen people injured after vehicle crashes into crowd in Los Angeles He was transported to a local hospital where he was initially listed in critical condition. He died at the hospital on July 17 at 2:36 p.m., police said. Officials have not yet released the name of the man nor whether he was a visitor to the facility, a patient or if he worked there. Police did not elaborate on the type or extent of the man's injuries. According to police, the machine's magnetic field immediately attracted "a large metallic chain" the victim wore, which quickly pulled him into the machine and "resulted in a medical episode." The investigation into the incident is ongoing, police said. USA TODAY contacted Nassau Open MRI on July 18 but has not received a response. Magnetic resonance imaging, or MRI, is a non-invasive 3D imaging technology used to examine patients' organs, tissues and skeletal system for diagnostic purposes, according to the Mayo Clinic. Adverse events from MRI scans "are rare," according to the U.S. Food and Drug Administration (FDA), which regulates MRI equipment. Millions of MRI scans are performed across the nation every year, the FDA wrote on its website. The agency said it receives around 300 incident reports annually involving MRI scanners and coils from manufacturers, distributors, user facilities and patients. Most of the reports, according to the FDA, include burns, as well as injuries from "projectile events" (objects being drawn toward the MRI scanner). High-powered magnets in the machine quickly draw items, especially metal, into the machine's chamber. "The strong magnetic field can attract metallic objects, potentially causing them to become projectiles and injure patients," the FDA's website reads.
